ASPAGNII (TM) May Revolutionise Cancer Treatment
India’s first indigenous tumour antigen SPAG9 was discovered by Dr Anil Suri in 1998who is heading the Cancer Research Program at NII. In a recentdevelopment, theSPAG9 antigen has received the trademark ASPAGNIITM. Currently, ASPAGNIITM is being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer.